Gastroenterology | Home | MIMS Malaysia

Malaysia
Search
Sign In

Gastroenterology Search

Gastroenterology

Gastroenterology

Home News Diseases Conferences Special Reports Multimedia

Gastric cancer risk elevated in T2D patients treated for H. pylori

Roshini Claire Anthony, Yesterday

Individuals with type 2 diabetes mellitus (T2D) may be at risk of developing gastric cancer even after receiving Helicobacter pylori (H. pylori) eradication therapy, demonstrated a study from Hong Kong.

PPI not beneficial to patients receiving low-dose anticoagulation, aspirin

2 days ago

Use of the proton pump inhibitor (PPI) pantoprazole does not cut the risk of upper gastrointestinal events but may reduce the risk of bleeding from gastroduodenal lesions in patients on low-dose anticoagulants and/or antiplatelet therapy, a study has shown.

Immunomodulator–anti-TNF combo cuts risk of treatment ineffectiveness in CD but not UC

Jairia Dela Cruz, 2 days ago

Initiating therapy with a combination of immune modulators (IM) and antitumour necrosis factor (anti-TNF) agents appears to reduce the incidence of therapeutic ineffectiveness in patients with Crohn’s disease (CD) but not those with ulcerative colitis (UC), a recent study has found.

Besifovir safe, effective for treating chronic hepatitis B virus infection in Asians

Jairia Dela Cruz, 4 days ago

Besifovir dipivoxil maleate has antiviral efficacy against chronic hepatitis B that is similar to that of tenofovir disoproxil fumarate but with a lower impact on bone and renal safety, as shown in the results of a phase III trial involving Asian patients.

Predictors of cognitive behavioural therapy success in managing supragastric belching

6 days ago

In the management of supragastric belching (SGB) with cognitive behavioural therapy (CBT), factors such as number of SGB and hypervigilance score at baseline as well as proficiency during treatment help predict CBT outcomes, according to a study.

Female vs male IBD patients more likely to cease TNF‐α inhibitor therapy due to side effects

Jairia Dela Cruz, 15 Aug 2019

Persistence to treatment with a tumour necrosis factor (TNF)‐α inhibitor for inflammatory bowel disease (IBD) appears to be lower among female than male patients, as reported in a recent study. Treatment discontinuation is driven mainly by side effects, the rate of which being higher in women than in men.

PyloBalance as an adjunct therapy in the treatment of H. pylori infections

17 Jul 2019

All Helicobacters are urease-positive, able to convert aminoacids and urea into ammonia to neutralize stomach acid, andhighly mobile – characteristics that help them invade the mucosallayer to evade the body’s immune response. Helicobacter pylori(H. pylori) is linked to peptic ulcer disease, chronic gastritis,gastric mucosa-associated lymphoid tissue lymphoma, andearly gastric cancer. The infection rate of H. pylori is over 80% indeveloping countries and 20–50% in industrialized nations, withover 4.4 billion people testing positive for the bacteria in 2015.1,2

MIMS Gasteroenterology Supplement June 2018

19 Jun 2018

There is an increasing number of studies that shed light on the importance of our gut microbiota. Probiotics are live microorganisms that confer health benefits on the host when administered in adequate amounts. With new data emerging about their proposed benefits in maintaining intestinal health, probiotics continue to gain popularity amongst consumers.

GPs in co-management of IBD: The follow-up phase

02 Oct 2017

Last August, the article 'Role of General Practitioners in Early Detection of Inflammatory Bowel Disease' highlighted proper screening and early specialist referral by the general practitioner (GP) as vital components in reducing the burden of inflammatory bowel disease (IBD). This year, the focus is on the role of GPs in co-managing a patient with IBD at the follow-up phase.

An update on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

29 Sep 2017

Nonalcoholic fatty liver disease (NAFLD), including simple steatosis and nonalcoholic steatohepatitis (NASH), is widely considered as the liver manifestation of the metabolic syndrome. It is a major cause of liver disease worldwide and its prevalence is expected to rise in tandem with the rising prevalence of obesity and diabetes mellitus. Recently, MIMS Doctor spoke to Associate Professor Dr Wah Kheong Chan, a Consultant Physician and Gastroenterologist at the University of Malaya Medical Centre and University of Malaya Specialist Centre, to provide an update on NAFLD, with a particular emphasis on the use of silymarin for the treatment of NASH. Here are the highlights from the interview.

The gentle approach towards effective management of constipation

29 Sep 2017

Constipation is a common disorder which adversely affects the wellbeing and quality of life of patients.¹ Recently, MIMS Doctor spoke to Associate Prof Dr Raja Affendi Raja Ali on the landscape of constipation in Malaysia, emphasizing on effective and early management of the condition.

TAS-118 + oxaliplatin outdoes S-1 + cisplatin in improving survival in advanced gastric cancer

Roshini Claire Anthony, 15 Jul 2019

The combination of TAS-118 and oxaliplatin led to significantly greater survival compared with the S-1 and cisplatin combination in patients with metastatic or recurrent HER2-negative gastric cancer, the phase III SOLAR* study showed.

Dose reduction has little impact on regorafenib tolerability, efficacy not compromised

Roshini Claire Anthony, 12 Jul 2019

Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.

Ramucirumab ups survival in advanced HCC regardless of prior TACE

Pearl Toh, 11 Jul 2019

The survival benefit with ramucirumab was consistent in patients with advanced hepatocellular carcinoma (HCC) and high alpha-fetoprotein (AFP) levels regardless of whether they were previously treated with transarterial chemoembolization (TACE), a post hoc analysis of pooled data from the REACH/REACH-2 studies shows.

Add-on bevacizumab improves efficacy of trifluridine/tipiracil in mCRC

Elaine Soliven, 11 Jul 2019

Adding bevacizumab to trifluridine/tipiracil (FTD/TPI) significantly improves progression-free survival (PFS) and overall survival (OS) compared with FTD/TPI in patients with chemorefractory metastatic colorectal cancer (mCRC), according to a study presented at ESMO GI 2019.

Triplet-targeted therapy a BEACON of hope for patients with BRAF-V600E mCRC

Pearl Toh, 09 Jul 2019

A triple-drug combination therapy comprising encorafenib, binimetinib, and cetuximab significantly improved survival compared with the current standard of care chemotherapy in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had failed one or two prior treatments, according to the BEACON CRC study presented at the recent ESMO World Congress on Gastrointestinal Cancer (ESMO GI).

Encouraging efficacy with glecaprevir-pibrentasvir combo in HCV

Roshini Claire Anthony, 10 May 2019

Treatment with the direct-acting antiviral (DAA) combination of glecaprevir and pibrentasvir led to encouraging sustained virological response (SVR) among individuals with hepatitis C virus (HCV) infection, results of two real-world studies presented at the International Liver Congress™ (ILC 2019) showed.

Rising risk of NAFLD-related mortality in HIV+ individuals

Roshini Claire Anthony, 07 May 2019

The trend in liver disease-related mortality in individuals with HIV has changed, with a reduction in the incidence of viral hepatitis-related deaths and an increase in non-alcoholic fatty liver disease (NAFLD)-related deaths, according to a study presented at the International Liver Congress™ (ILC 2019).

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!